Clinical Trial Update: BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD [Phase 2]

View source ↗

Summary

Phase 2 trial comparing once-daily versus twice-daily BI 1744 CL with the Respimat inhaler in chronic obstructive pulmonary disease; trial completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• BI 1744 CL

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 2 | Status: COMPLETED | Results posted: 2014-07-01